Wavelength-Pharmaceuticals-Insert
X

Find Novel Oncology Drugs in Clinical Development in GERMANY

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): T cell immunotherapies

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Arya Sciences Acquisition Corp

            Deal Size: $252.0 million Upfront Cash: Undisclosed

            Deal Type: Agreement March 17, 2020

            Details:

            Deal aims at identifying cancer targets and developing the right TCRs for immunotherapies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GlymaxX

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 08, 2020

            Details:

            ProBioGen AG, has signed a commercial license agreement with Roche for applying ProBioGen’s proprietary GlymaxX® technology to boost the antibody’s ADCC anti-tumor activity.